Clinical trial
Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic…
NCT00389363 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00389363 |
|---|---|
| Title | Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects |
| Official title | A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | ALK HDM tablet |
| Enrollment | 800 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Oct 18, 2006 |
| Last update posted | Aug 17, 2010 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: